LX-9211 : 판매 예측 및 시장 규모(2034년)

Key Factors Driving LX-9211 Growth

1. Novel, first-in-class mechanism (AAK1 inhibition)

• LX-9211 is a selective adaptor-associated kinase 1 (AAK1) inhibitor, a new, non-opioid pain pathway.
• AAK1 inhibition reduces neurotransmitter recycling involved in pain signaling without affecting opioid pathways.
• Differentiation from gabapentinoids/opioids -> potential best-in-class positioning
• Supports premium pricing and strong uptake if approved

2. Positive Phase II efficacy with statistically significant pain reduction

• In the RELIEF-DPN-1 Phase II trial:
• Pain reduction: -1.39 (low dose) vs -0.72 placebo (p=0.007)
• In the Phase IIb PROGRESS study (~496 patients):
• Demonstrated meaningful pain reduction vs placebo at optimized dose
• Clinically validated efficacy -> key derisking milestone
• Supports advancement into late-stage development

3. Advancement into Phase III (major value inflection point)

• Lexicon selected 10 mg once-daily dose for Phase III development based on efficacy/tolerability balance
• ~600 patients exposed across Phase II programs, strengthening dataset
• Transition to Phase III significantly increases probability of commercialization
• Typically the stage where partnering and valuation inflection occur

4. Large and underserved neuropathic pain market

• ~9 million patients in the US alone suffer from diabetic peripheral neuropathic pain (DPNP)
• Patients often cycle through multiple therapies with inadequate relief

5. Favorable non-opioid profile amid opioid crisis

• LX-9211 is an oral, non-opioid therapy, aligning with global efforts to reduce opioid use
• Structural tailwind from opioid-sparing treatment guidelines
• Improves physician and payer acceptance

LX-9211 Recent Developments

In March 2025, Lexicon Pharmaceuticals announced the topline results from the PROGRESS Phase IIb study evaluating Pilavapadin (LX9211), an oral, non-opioid investigational adaptor-associated kinase 1 (AAK1) inhibitor in adult patients with moderate to severe diabetic peripheral neuropathic pain (DPNP).

"LX-9211 Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of LX-9211 for potential indication like Neuropathic pain and Postherpetic neuralgia in the 7MM. A detailed picture of LX-9211's existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the LX-9211 for potential indications. The LX-9211 market report provides insights about LX-9211's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current LX-9211 performance, future market assessments inclusive of the LX-9211 market forecast analysis for potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of LX-9211 sales forecasts, along with factors driving its market.

LX-9211 Drug Summary

LX-9211 is an investigational, orally administered small molecule developed by Lexicon Pharmaceuticals that targets pathways involved in neuropathic pain signaling. LX9211 is designed to selectively inhibit adaptor-associated kinase 1 (AAK1), a regulator of intracellular trafficking implicated in pain transmission, thereby reducing abnormal neuronal signaling without directly affecting opioid pathways. It has been evaluated in clinical trials for conditions such as diabetic peripheral neuropathic pain and post-herpetic neuralgia, where early studies have shown reductions in pain scores and a generally favorable safety profile. Its non-opioid mechanism and oral administration position it as a potentially important alternative in chronic pain management, though it remains in clinical development and has not yet received regulatory approval. The report provides LX-9211's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the LX-9211 Market Report

The report provides insights into:

• A comprehensive product overview including the LX-9211 MoA, description, dosage and administration, research and development activities in potential indication like Neuropathic pain and Postherpetic neuralgia.
• Elaborated details on LX-9211 regulatory milestones and other development activities have been provided in LX-9211 market report.
• The report also highlights LX-9211's cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The LX-9211 market report also covers the patents information, generic entry and impact on cost cut.
• The LX-9211 market report contains current and forecasted LX-9211 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The LX-9211 market report also features the SWOT analysis with analyst views for LX-9211 in potential indications.

Methodology:

The LX-9211 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

LX-9211 Analytical Perspective by DelveInsight

• In-depth LX-9211 Market Assessment

This LX-9211 sales market forecast report provides a detailed market assessment of LX-9211 for potential indication like Neuropathic pain and Postherpetic neuralgia in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted LX-9211 sales data uptil 2034.

• LX-9211 Clinical Assessment

The LX-9211 market report provides the clinical trials information of LX-9211 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

LX-9211 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

LX-9211 Market Potential & Revenue Forecast

• Projected market size for the LX-9211 and its key indications
• Estimated LX-9211 sales potential (LX-9211 peak sales forecasts)
• LX-9211 Pricing strategies and reimbursement landscape

LX-9211 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• LX-9211 Market positioning compared to existing treatments
• LX-9211 Strengths & weaknesses relative to competitors

LX-9211 Regulatory & Commercial Milestones

• LX-9211 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

LX-9211 Clinical Differentiation

• LX-9211 Efficacy & safety advantages over existing drugs
• LX-9211 Unique selling points

LX-9211 Market Report Highlights

• In the coming years, the LX-9211 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The LX-9211 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence LX-9211's dominance.
• Other emerging products for Neuropathic pain and Postherpetic neuralgia are expected to give tough market competition to LX-9211 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of LX-9211 in potential indications.
• Analyse LX-9211 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted LX-9211 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of LX-9211 in potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of LX-9211? How strong is LX-9211's clinical and commercial performance?
• What is LX-9211's clinical trial status in each individual indications such as Neuropathic pain and Postherpetic neuralgia and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the LX-9211 Manufacturers?
• What are the key designations that have been granted to LX-9211 for potential indications? How are they going to impact LX-9211's penetration in various geographies?
• What is the current and forecasted LX-9211 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of LX-9211 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to LX-9211 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is LX-9211? What is the duration of therapy and what are the geographical variations in cost per patient?

Table of Contents

1. Report Introduction

2. LX-9211 Overview in potential indication like Neuropathic pain and Postherpetic neuralgia

• 2.1. Product Detail
• 2.2. LX-9211 Clinical Development
  • 2.2.1. LX-9211 Clinical studies
  • 2.2.2. LX-9211 Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. LX-9211 Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging LX-9211 Therapies)

5. LX-9211 Market Assessment

• 5.1. LX-9211 Market Outlook in potential indications
• 5.2. 7MM Analysis
  • 5.2.1. LX-9211 Market Size in the 7MM for potential indications
• 5.3. Country-wise Market Analysis
  • 5.3.1. LX-9211 Market Size in the United States for potential indications
  • 5.3.2. LX-9211 Market Size in Germany for potential indications
  • 5.3.3. LX-9211 Market Size in France for potential indications
  • 5.3.4. LX-9211 Market Size in Italy for potential indications
  • 5.3.5. LX-9211 Market Size in Spain for potential indications
  • 5.3.6. LX-9211 Market Size in the United Kingdom for potential indications
  • 5.3.7. LX-9211 Market Size in Japan for potential indications

6. LX-9211 SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options